HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: Long-term results

Mariantonietta Colozza, Angelo Sidoni, Anna Maria Mosconi, Antonio Cavaliere, Giancarlo Bisagni, Stefania Gori, Verena De Angelis, Antonio Frassoldati, Roberta Cherubini, Alberto Rosa Bian, Carmelina Rodinò, Bruno Mazzocchi, Zhasmina Mihailova, Emilio Bucciarelli, Maurizio Tonato

Research output: Contribution to journalArticle

Abstract

Background: HER2 overexpression/amplification has been reported to be a predictor of prognosis in breast cancer and a potential marker for selecting the optimal adjuvant chemotherapy. Patients and Methods: HER2 expression and its interaction with treatment were retrospectively evaluated in 266 of 348 patients in a trial comparing adjuvant CMF (cyclophosphamide/methotrexate/5- fluorouracil) with weekly epirubicin in stage I/II breast cancer. HER2 expression was determined by immunohistochemistry (IHC) using the monoclonal antibody CB11. Initially, any cell showing definite membrane staining was counted, and HER2 overexpression was analyzed as a continuous variable and as a dichotomous variable, with a cutoff of > 50% of positively stained cells. Subsequently, the same slides were reanalyzed with the HercepTest®. Results: Of the 266 tumors immunostained for HER2, 34% exhibited nearly homogeneous staining with > 50% positive cells. When the HercepTest® was applied, 8% of tumors were IHC 3+ and 8% were IHC 2+. At 8 years, no statistically significant difference in relapse-free survival (RFS) and overall survival (OS) was observed between the treatment arms in patients with low versus high HER2 overexpression, although the number of events is low. The OS was statistically shorter in patients with high HER2 overexpression in the CMF arm, whereas no difference was observed in the epirubicin arm, suggesting that patients whose cancer overexpresses HER2 could benefit more from anthracycline-based therapy. Conclusion: HER2 overexpression was associated with a poorer OS but not a poorer RFS. However, a Cox regression model did not confirm the prognostic role of HER2 for OS.

Original languageEnglish
Pages (from-to)253-259
Number of pages7
JournalClinical Breast Cancer
Volume6
Issue number3
DOIs
Publication statusPublished - 2005

Fingerprint

Epirubicin
Methotrexate
Fluorouracil
Cyclophosphamide
Breast Neoplasms
Survival
Immunohistochemistry
Staining and Labeling
Recurrence
Neoplasms
Anthracyclines
Adjuvant Chemotherapy
Proportional Hazards Models
Therapeutics
Monoclonal Antibodies
Membranes

Keywords

  • Adjuvant chemotherapy
  • Estrogen receptor
  • HercepTest®
  • Progesterone receptor

ASJC Scopus subject areas

  • Cancer Research

Cite this

HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer : Long-term results. / Colozza, Mariantonietta; Sidoni, Angelo; Mosconi, Anna Maria; Cavaliere, Antonio; Bisagni, Giancarlo; Gori, Stefania; De Angelis, Verena; Frassoldati, Antonio; Cherubini, Roberta; Bian, Alberto Rosa; Rodinò, Carmelina; Mazzocchi, Bruno; Mihailova, Zhasmina; Bucciarelli, Emilio; Tonato, Maurizio.

In: Clinical Breast Cancer, Vol. 6, No. 3, 2005, p. 253-259.

Research output: Contribution to journalArticle

Colozza, M, Sidoni, A, Mosconi, AM, Cavaliere, A, Bisagni, G, Gori, S, De Angelis, V, Frassoldati, A, Cherubini, R, Bian, AR, Rodinò, C, Mazzocchi, B, Mihailova, Z, Bucciarelli, E & Tonato, M 2005, 'HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: Long-term results', Clinical Breast Cancer, vol. 6, no. 3, pp. 253-259. https://doi.org/10.3816/CBC.2005.n.028
Colozza, Mariantonietta ; Sidoni, Angelo ; Mosconi, Anna Maria ; Cavaliere, Antonio ; Bisagni, Giancarlo ; Gori, Stefania ; De Angelis, Verena ; Frassoldati, Antonio ; Cherubini, Roberta ; Bian, Alberto Rosa ; Rodinò, Carmelina ; Mazzocchi, Bruno ; Mihailova, Zhasmina ; Bucciarelli, Emilio ; Tonato, Maurizio. / HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer : Long-term results. In: Clinical Breast Cancer. 2005 ; Vol. 6, No. 3. pp. 253-259.
@article{51842f38c6ca4abe98ad5cd83e88a64f,
title = "HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: Long-term results",
abstract = "Background: HER2 overexpression/amplification has been reported to be a predictor of prognosis in breast cancer and a potential marker for selecting the optimal adjuvant chemotherapy. Patients and Methods: HER2 expression and its interaction with treatment were retrospectively evaluated in 266 of 348 patients in a trial comparing adjuvant CMF (cyclophosphamide/methotrexate/5- fluorouracil) with weekly epirubicin in stage I/II breast cancer. HER2 expression was determined by immunohistochemistry (IHC) using the monoclonal antibody CB11. Initially, any cell showing definite membrane staining was counted, and HER2 overexpression was analyzed as a continuous variable and as a dichotomous variable, with a cutoff of > 50{\%} of positively stained cells. Subsequently, the same slides were reanalyzed with the HercepTest{\circledR}. Results: Of the 266 tumors immunostained for HER2, 34{\%} exhibited nearly homogeneous staining with > 50{\%} positive cells. When the HercepTest{\circledR} was applied, 8{\%} of tumors were IHC 3+ and 8{\%} were IHC 2+. At 8 years, no statistically significant difference in relapse-free survival (RFS) and overall survival (OS) was observed between the treatment arms in patients with low versus high HER2 overexpression, although the number of events is low. The OS was statistically shorter in patients with high HER2 overexpression in the CMF arm, whereas no difference was observed in the epirubicin arm, suggesting that patients whose cancer overexpresses HER2 could benefit more from anthracycline-based therapy. Conclusion: HER2 overexpression was associated with a poorer OS but not a poorer RFS. However, a Cox regression model did not confirm the prognostic role of HER2 for OS.",
keywords = "Adjuvant chemotherapy, Estrogen receptor, HercepTest{\circledR}, Progesterone receptor",
author = "Mariantonietta Colozza and Angelo Sidoni and Mosconi, {Anna Maria} and Antonio Cavaliere and Giancarlo Bisagni and Stefania Gori and {De Angelis}, Verena and Antonio Frassoldati and Roberta Cherubini and Bian, {Alberto Rosa} and Carmelina Rodin{\`o} and Bruno Mazzocchi and Zhasmina Mihailova and Emilio Bucciarelli and Maurizio Tonato",
year = "2005",
doi = "10.3816/CBC.2005.n.028",
language = "English",
volume = "6",
pages = "253--259",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer

T2 - Long-term results

AU - Colozza, Mariantonietta

AU - Sidoni, Angelo

AU - Mosconi, Anna Maria

AU - Cavaliere, Antonio

AU - Bisagni, Giancarlo

AU - Gori, Stefania

AU - De Angelis, Verena

AU - Frassoldati, Antonio

AU - Cherubini, Roberta

AU - Bian, Alberto Rosa

AU - Rodinò, Carmelina

AU - Mazzocchi, Bruno

AU - Mihailova, Zhasmina

AU - Bucciarelli, Emilio

AU - Tonato, Maurizio

PY - 2005

Y1 - 2005

N2 - Background: HER2 overexpression/amplification has been reported to be a predictor of prognosis in breast cancer and a potential marker for selecting the optimal adjuvant chemotherapy. Patients and Methods: HER2 expression and its interaction with treatment were retrospectively evaluated in 266 of 348 patients in a trial comparing adjuvant CMF (cyclophosphamide/methotrexate/5- fluorouracil) with weekly epirubicin in stage I/II breast cancer. HER2 expression was determined by immunohistochemistry (IHC) using the monoclonal antibody CB11. Initially, any cell showing definite membrane staining was counted, and HER2 overexpression was analyzed as a continuous variable and as a dichotomous variable, with a cutoff of > 50% of positively stained cells. Subsequently, the same slides were reanalyzed with the HercepTest®. Results: Of the 266 tumors immunostained for HER2, 34% exhibited nearly homogeneous staining with > 50% positive cells. When the HercepTest® was applied, 8% of tumors were IHC 3+ and 8% were IHC 2+. At 8 years, no statistically significant difference in relapse-free survival (RFS) and overall survival (OS) was observed between the treatment arms in patients with low versus high HER2 overexpression, although the number of events is low. The OS was statistically shorter in patients with high HER2 overexpression in the CMF arm, whereas no difference was observed in the epirubicin arm, suggesting that patients whose cancer overexpresses HER2 could benefit more from anthracycline-based therapy. Conclusion: HER2 overexpression was associated with a poorer OS but not a poorer RFS. However, a Cox regression model did not confirm the prognostic role of HER2 for OS.

AB - Background: HER2 overexpression/amplification has been reported to be a predictor of prognosis in breast cancer and a potential marker for selecting the optimal adjuvant chemotherapy. Patients and Methods: HER2 expression and its interaction with treatment were retrospectively evaluated in 266 of 348 patients in a trial comparing adjuvant CMF (cyclophosphamide/methotrexate/5- fluorouracil) with weekly epirubicin in stage I/II breast cancer. HER2 expression was determined by immunohistochemistry (IHC) using the monoclonal antibody CB11. Initially, any cell showing definite membrane staining was counted, and HER2 overexpression was analyzed as a continuous variable and as a dichotomous variable, with a cutoff of > 50% of positively stained cells. Subsequently, the same slides were reanalyzed with the HercepTest®. Results: Of the 266 tumors immunostained for HER2, 34% exhibited nearly homogeneous staining with > 50% positive cells. When the HercepTest® was applied, 8% of tumors were IHC 3+ and 8% were IHC 2+. At 8 years, no statistically significant difference in relapse-free survival (RFS) and overall survival (OS) was observed between the treatment arms in patients with low versus high HER2 overexpression, although the number of events is low. The OS was statistically shorter in patients with high HER2 overexpression in the CMF arm, whereas no difference was observed in the epirubicin arm, suggesting that patients whose cancer overexpresses HER2 could benefit more from anthracycline-based therapy. Conclusion: HER2 overexpression was associated with a poorer OS but not a poorer RFS. However, a Cox regression model did not confirm the prognostic role of HER2 for OS.

KW - Adjuvant chemotherapy

KW - Estrogen receptor

KW - HercepTest®

KW - Progesterone receptor

UR - http://www.scopus.com/inward/record.url?scp=32944459739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944459739&partnerID=8YFLogxK

U2 - 10.3816/CBC.2005.n.028

DO - 10.3816/CBC.2005.n.028

M3 - Article

C2 - 16137437

AN - SCOPUS:32944459739

VL - 6

SP - 253

EP - 259

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 3

ER -